Skip to content

Study · Measured the body's own peptide · 2024

2 results

Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure.

Asil H, Demiryürek AT, Düzen IV, Büyükcelebi O, Saracaloglu A, Demirkiran C, Demiryürek Ş

European journal of pharmacology23 Aug 2024Cited by 8 (Europe PMC)

PMID39182552 (opens in a new tab)DOI10.1016/j.ejphar.2024.176934 (opens in a new tab)PepBankPUB-39182552
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In diabetic patients with heart failure with reduced ejection fraction, SGLT2 inhibitor use had no marked effect on serum humanin levels.

    In plain wordsIn diabetic patients with heart failure, SGLT2 inhibitors did not markedly change the body's own humanin levels.

    Peptide
    Humanin
    Outcome
    No significant changeSerum humanin level with SGLT2 inhibitor use
    Study

    n = 111

    Outcome group
    Mitochondrial function · Cardiovascular

    Source sentences

    Summary
    Although SGLT2 inhibitors had no marked effect on humanin levels, they significantly augmented MOTS-c levels when compared to the control.
    2 context sentences
    Summary · context
    A total of 74 adult diabetic patients with HFrEF and 37 healthy controls were included in this prospective study.
    Summary · context
    Half of the patients were using SGLT2 inhibitors (empagliflozin or dapagliflozin) for at least two months.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In diabetic patients with heart failure with reduced ejection fraction who used SGLT2 inhibitors, serum MOTS‑c levels were higher than in healthy controls.

    In plain wordsIn diabetic patients with heart failure, those using SGLT2 drugs had higher levels of the body's own MOTS‑c than healthy people.

    Peptide
    MOTS-c
    Outcome
    IncreaseSerum MOTS-c level
    Study

    n: not reported in source

    Comparator
    Healthy controls
    Outcome group
    Mitochondrial function · Cardiovascular

    Source sentences

    Summary
    Although SGLT2 inhibitors had no marked effect on humanin levels, they significantly augmented MOTS-c levels when compared to the control.
    2 context sentences
    Summary · context
    A total of 74 adult diabetic patients with HFrEF and 37 healthy controls were included in this prospective study.
    Summary · context
    Half of the patients were using SGLT2 inhibitors (empagliflozin or dapagliflozin) for at least two months.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    10 Oct 2026, 08:19 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.